Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?
ABSTRACTObjectives: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most important curative modality for several hematologic malignancies, but an HLA-matched sibling or unrelated donor is not always available, particularly for ethnic minorities and multiethnic families. We have...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2242176 |
| _version_ | 1797756130677489664 |
|---|---|
| author | Juan Carlos Olivares-Gazca María de Lourdes Pastelín-Martínez Merittzel Abigail Montes-Robles Moisés Manuel Gallardo-Pérez Edgar J. Hernández-Flores Max Robles-Nasta Daniela Sánchez-Bonilla Guillermo J. Ruiz-Delgado Guillermo J. Ruiz-Argüelles |
| author_facet | Juan Carlos Olivares-Gazca María de Lourdes Pastelín-Martínez Merittzel Abigail Montes-Robles Moisés Manuel Gallardo-Pérez Edgar J. Hernández-Flores Max Robles-Nasta Daniela Sánchez-Bonilla Guillermo J. Ruiz-Delgado Guillermo J. Ruiz-Argüelles |
| author_sort | Juan Carlos Olivares-Gazca |
| collection | DOAJ |
| description | ABSTRACTObjectives: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most important curative modality for several hematologic malignancies, but an HLA-matched sibling or unrelated donor is not always available, particularly for ethnic minorities and multiethnic families. We have shown that Haplo-HSCT can be conducted safely on an outpatient basis, using peripheral blood stem cells; this leading into substantial decreases in the costs. Methods: In this study twenty-one patients prospectively received the conventional dose of post-transplantation cyclophosphamide (PTCy): (50 mg/Kg on days 3 and 4), whereas 10 were given reduced doses of the drug (25 mg/Kg on days 3 and 4). Results: According to the statistical analysis, the two comparative groups (PTCy 50 mg/kg vs PTCy 25 mg/kg) had no significant difference in terms of age, sex, hematological recovery, and type of conditioning regimen. The median OS for the group PTCy 50 mg/kg is 5.7 months meanwhile for the group PTCy 25 mg/kg the median is 6.4 months. The median follow up for entire group is 4.5 months (IQR: 1.1–18.9 mo). Conclusion: These results could indicate that the Cy-dependent hematological toxicity can be reduced without compromising its effectivity. This preliminary observation may be considered as an idea to conduct prospective randomized studies to explore the possibility of significantly reducing the doses of PT-Cy in the setting of Haplo-HSCT.Trial registration: ClinicalTrials.gov identifier: NCT05780554. |
| first_indexed | 2024-03-12T17:56:08Z |
| format | Article |
| id | doaj.art-086f44f5a5744719b3af36c70ede2a5b |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-12T17:56:08Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-086f44f5a5744719b3af36c70ede2a5b2023-08-02T14:25:25ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2242176Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?Juan Carlos Olivares-Gazca0María de Lourdes Pastelín-Martínez1Merittzel Abigail Montes-Robles2Moisés Manuel Gallardo-Pérez3Edgar J. Hernández-Flores4Max Robles-Nasta5Daniela Sánchez-Bonilla6Guillermo J. Ruiz-Delgado7Guillermo J. Ruiz-Argüelles8Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoABSTRACTObjectives: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most important curative modality for several hematologic malignancies, but an HLA-matched sibling or unrelated donor is not always available, particularly for ethnic minorities and multiethnic families. We have shown that Haplo-HSCT can be conducted safely on an outpatient basis, using peripheral blood stem cells; this leading into substantial decreases in the costs. Methods: In this study twenty-one patients prospectively received the conventional dose of post-transplantation cyclophosphamide (PTCy): (50 mg/Kg on days 3 and 4), whereas 10 were given reduced doses of the drug (25 mg/Kg on days 3 and 4). Results: According to the statistical analysis, the two comparative groups (PTCy 50 mg/kg vs PTCy 25 mg/kg) had no significant difference in terms of age, sex, hematological recovery, and type of conditioning regimen. The median OS for the group PTCy 50 mg/kg is 5.7 months meanwhile for the group PTCy 25 mg/kg the median is 6.4 months. The median follow up for entire group is 4.5 months (IQR: 1.1–18.9 mo). Conclusion: These results could indicate that the Cy-dependent hematological toxicity can be reduced without compromising its effectivity. This preliminary observation may be considered as an idea to conduct prospective randomized studies to explore the possibility of significantly reducing the doses of PT-Cy in the setting of Haplo-HSCT.Trial registration: ClinicalTrials.gov identifier: NCT05780554.https://www.tandfonline.com/doi/10.1080/16078454.2023.2242176Allogeneic hematopoietic stem cell transplantationPost-transplantation CyclophosphamideGraft-versus-host disease; Outpatient; Cytokine release syndrome; Allograft; Haploidentical hematopoietic stem cell transplantation; Acute leukemia |
| spellingShingle | Juan Carlos Olivares-Gazca María de Lourdes Pastelín-Martínez Merittzel Abigail Montes-Robles Moisés Manuel Gallardo-Pérez Edgar J. Hernández-Flores Max Robles-Nasta Daniela Sánchez-Bonilla Guillermo J. Ruiz-Delgado Guillermo J. Ruiz-Argüelles Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? Hematology Allogeneic hematopoietic stem cell transplantation Post-transplantation Cyclophosphamide Graft-versus-host disease; Outpatient; Cytokine release syndrome; Allograft; Haploidentical hematopoietic stem cell transplantation; Acute leukemia |
| title | Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? |
| title_full | Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? |
| title_fullStr | Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? |
| title_full_unstemmed | Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? |
| title_short | Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? |
| title_sort | can doses of post transplantation cyclophosphamide in haploidentical stem cell allografts be reduced |
| topic | Allogeneic hematopoietic stem cell transplantation Post-transplantation Cyclophosphamide Graft-versus-host disease; Outpatient; Cytokine release syndrome; Allograft; Haploidentical hematopoietic stem cell transplantation; Acute leukemia |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2242176 |
| work_keys_str_mv | AT juancarlosolivaresgazca candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT mariadelourdespastelinmartinez candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT merittzelabigailmontesrobles candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT moisesmanuelgallardoperez candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT edgarjhernandezflores candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT maxroblesnasta candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT danielasanchezbonilla candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT guillermojruizdelgado candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced AT guillermojruizarguelles candosesofposttransplantationcyclophosphamideinhaploidenticalstemcellallograftsbereduced |